Browse hierarchy: [General Hospital (HO)](/submissions/HO) → [Subpart F — General Hospital and Personal Use Therapeutic Devices](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices) → [21 CFR 880.5445](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/880.5445) → OKL — Intravascular Administration Set, Automated Air Removal System # OKL · Intravascular Administration Set, Automated Air Removal System _General Hospital · 21 CFR 880.5445 · Class 2_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/OKL ## Overview - **Product Code:** OKL - **Device Name:** Intravascular Administration Set, Automated Air Removal System - **Regulation:** [21 CFR 880.5445](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/880.5445) - **Device Class:** 2 - **Review Panel:** [General Hospital](/submissions/HO) ## Identification An intravascular administration set, automated air removal system, is a prescription device used to detect and automatically remove air from an intravascular administration set with minimal to no interruption in the flow of the intravascular fluid. The device may include an air identification mechanism, software, an air removal mechanism, tubing, apparatus to collect removed air, and safety control mechanisms to address hazardous situations. ## Classification Rationale Class II (special controls). The special controls for this device are: ## Special Controls In combination with the general controls of the FD&C Act, the AirPurge System is subject to the following special controls: - (1) Provide an argument demonstrating that all reasonably foreseeable hazards have been adequately addressed with respect to the persons for whose use the device is represented or intended and the conditions of use for the device, which includes the following: - (i) Description of the device indications for use, design and technology, use environments, and users in sufficient detail to determine that the device complies with all special controls. - (ii) Demonstrate that controls are implemented to address device system hazards and their causes. - (iii)Include a justification supporting the acceptability criteria for each hazard control. - (iv)A traceability analysis demonstrating that all credible hazards have at least one corresponding control and that all controls have been verified and validated in the final device design. - (2) Appropriate software verification, validation, and hazard analysis must be performed. - (3) The device parts that directly or indirectly contact the patient must be demonstrated to be biocompatible. - (4) Performance data must demonstrate the sterility of fluid path contacting components and the shelf-life of these components. - (5) The device must be designed and tested for electrical safety and electromagnetic compatibility (EMC). - (6) Non-clinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: - (i) Device system and component reliability testing must be conducted. - (ii) Fluid ingress protection testing must be conducted. - (iii)Testing of safety controls must be performed to demonstrate adequate mitigation of hazardous situations, including sensor failure, flow control failure, improper device position, device malfunction, infusion delivery error, and release of air to the patient. - (7) A human factors validation study must demonstrate that use hazards are adequately addressed. - (8) The labeling must include the following: - (i) The device's air identification and removal response time. - (ii) The device's minimum air volume identification sensitivity. - (iii)The minimum and maximum flow rates at which the device is capable of reliably detecting and removing air. - (iv)Quantification of any fluid loss during device air removal operations as a function of flow rate. *Classification.* Class II (special controls). The special controls for this device are:(1) Provide an argument demonstrating that all reasonably foreseeable hazards have been adequately addressed with respect to the persons for whose use the device is represented or intended and the conditions of use for the device, which includes the following: (i) Description of the device indications for use, design, and technology, use environments, and users in sufficient detail to determine that the device complies with all special controls. (ii) Demonstrate that controls are implemented to address device system hazards and their causes. (iii) Include a justification supporting the acceptability criteria for each hazard control. (iv) A traceability analysis demonstrating that all credible hazards have at least one corresponding control and that all controls have been verified and validated in the final device design. (2) Appropriate software verification, validation, and hazard analysis must be performed. (3) The device parts that directly or indirectly contact the patient must be demonstrated to be biocompatible. (4) Performance data must demonstrate the sterility of fluid path contacting components and the shelf life of these components. (5) The device must be designed and tested for electrical safety and electromagnetic compatibility (EMC). (6) Nonclinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Device system and component reliability testing must be conducted. (ii) Fluid ingress protection testing must be conducted. (iii) Testing of safety controls must be performed to demonstrate adequate mitigation of hazardous situations, including sensor failure, flow control failure, improper device position, device malfunction, infusion delivery error, and release of air to the patient. (7) A human factors validation study must demonstrate that use hazards are adequately addressed. (8) The labeling must include the following: (i) The device's air identification and removal response time. (ii) The device's minimum air volume identification sensitivity. (iii) The minimum and maximum flow rates at which the device is capable of reliably detecting and removing air. (iv) Quantification of any fluid loss during device air removal operations as a function of flow rate. ## Recent Cleared Devices (2 of 2) | Record | Device Name | Applicant | Decision Date | Decision | | --- | --- | --- | --- | --- | | [K171954](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/OKL/K171954.md) | ClearLine IV | Clearline MD | Jan 25, 2018 | SESE | | [DEN080009](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/OKL/DEN080009.md) | AIRPURGE | Anesthesia Safety Products, LLC | Mar 4, 2014 | DENG | ## Top Applicants - Anesthesia Safety Products, LLC — 1 clearance - Clearline MD — 1 clearance --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/OKL](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/OKL) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com